单增李斯特菌毒力因子溶血素关键氨基酸位点在感染过程中的作用研究

【目的】探究单增李斯特菌溶血素O (listeriolysin O, LLO)中D3区域β8折叠片上第253位氨基酸(谷氨酰胺,Q)和第254位氨基酸(异亮氨酸,I)对单增李斯特菌(Listeria monocytogenes)感染生物学功能的影响。【方法】构建LLO_Q253A和LLO_I254A突变蛋白的原核表达菌株,以及利用同源重组方法构建hly_Q253A和hly_I254A突变株;通过表达纯化突变蛋白,测定溶血活性;比较LLO第253位Q和第254位I均突变成丙氨酸(A)后,对细菌体外生长能力、黏附侵袭、胞内迁移和增殖能力的影响。【结果】相应位点突变后,LLO蛋白均能够正常表达。在pH 6.5条件下,所有突变蛋白和突变株的溶血活性丧失。然而,在pH 5.5条件下,LLO_I254A和hly_I254A恢复了溶血活性。与野生株相比,突变株的体外生长、黏附能力和胞内增殖能力均无明显差异;突变株的侵袭能力和胞间迁移能力显著低于野生株。【结论】本研究证实第253位Q和第254位I均突变成A后,单增李斯特菌在pH 6.5条件下丧失溶血活性,并降低了感染宿主细胞的能力,但具体机制还有待进一步探索。本研究为深入探究LLO结构对单增李斯特菌生物学功能的影响奠定基础,对单增李斯特菌点突变株的构建具有一定参考意义。     

单增李斯特菌溶血素(LLO)的原核表达及其生物学活性鉴定

利用生物软件设计单增李斯特菌溶血素蛋白的基因hly的引物,通过PCR扩增hly基因,并将其克隆至PET28a(+)原核表达载体,转化大肠杆菌BL21进行优化表达。用镍柱纯化表达产物LLO,通过免疫印记鉴定其免疫原性,并通过溶血实验鉴定其溶血活性。琼脂糖凝胶电泳结果表明PCR扩增出1 590 bp的片段,经测序鉴定其序列同源性可达99%。SDS-PAGE结果表明诱导表达的产物大小约为58 kD,其最优化的表达条件是28°C下用0.1 mmol/L IPTG诱导6 h。Western blotting结果表明重组表达的LLO具有免疫原性;溶血实验表明重组表达的LLO具有较强的溶血活性,其溶血效价可达1:1 024。这为制备针对单增李斯特菌的单克隆抗体及其检测方法的建立奠定了基础。     

李斯特菌溶血素基因的原核表达及其生物学特性

李斯特菌溶血素(LLO)是产单核细胞李斯特菌的主要毒力因子,利用PCR技术从血清型4b的产单核细胞李斯特菌菌株中扩增出编码LLO的hly基因,经克隆筛选和测序鉴定后,构建成该基因的原核表达质粒pGEX6P1hly,SDSPAGE结果表明：LLO与谷胱甘肽在大肠杆菌中已融合表达,融合蛋白的分子量为82kD;溶血实验证明融合蛋白具有较强的裂解真核细胞膜的作用,表明表达产物LLO具有生物活性,其溶血效价达2.26×101.4 HU/mg,这为进一步研究其致病与免疫机理、单抗研制和疫苗设计提供了条件。     

单增李斯特菌核糖核酸酶Rnase Ⅲ RncS氨基酸突变对其降解RNA活性的影响

为研究单增李斯特菌(LM)核糖核酸酶Rnase Ⅲ RncS氨基酸突变对RNA降解活性的影响。利用生物信息学软件分析单核细胞增生李斯特菌(LM)野毒株SB5中rncS基因编码的Rnase Ⅲ的结构域,并选择关键氨基酸利用基因重叠延伸PCR(SOE-PCR)技术对其进行了基因突变;然后将rncS突变基因片段D50A、E122A克隆至表达载体pET-32a(+),在大肠杆菌中利用IPTG进行诱导表达;应用SDS-PAGE和Western Blot鉴定重组蛋白的表达情况及其抗原特异性;通过体外酶活试验研究其对RNA降解活性的影响。结构域分析结果显示,LM-Rnase Ⅲ氨基酸序列含有1个双链RNA结合结构域(DSRM)和1个核酸酶结构域(RIBOc),其中结构域RIBOc含有5个活性位点。SDS-PAGE检测结果显示,表达的重组突变型Rnase Ⅲ -D50A和Rnase Ⅲ -E122 A蛋白相对分子质量均为42.5 kD,与理论值相符;Western blot分析表明重组突变型Rnase Ⅲ -D50A和Rnase Ⅲ -E122A蛋白可与LM阳性血清发生免疫学反应。体外酶活实验表明,Rnase Ⅲ发挥降解活性依赖于Mn2+或Mg2+,将其第50位天冬氨酸突变后,Rnase Ⅲ RncS的降解活性有所降低(P0.001);第122位谷氨酸突变后,Rnase Ⅲ RncS降解活性极显著下降(P0.0001),提示第122位谷氨酸是维持LM Rnase Ⅲ RncS酶活性的关键位点。     

人干细胞生长因子Ca2+依赖糖识别结构域缺失突变体的重组表达及生物学活性的初步探讨

本作已有的研究结果证明,完整的人干细胞生长因子(hSCGF)没有种属特异性,即可以作用于小鼠骨髓造血细胞。这一点与在Ca^2 依赖糖识别结构域(CRD)缺失了78个氨基酸残基的截短分子(hSCGFβ)有所不同。本研究从hSCGF全长cDNA中完全删除了CRD结构域编码序列,进一步探讨CRD结构域的生物学功能。由于该突变体序列GC含量较高．因此将该缺失突变体序列克隆在GST融合表达载体中进行融合表达。通过低温(28℃)诱导,表达产物主要以可溶蛋白的形式存在。利用亲和层析纯化CRD结构域完全缺失的hSCGF突变体融合蛋白,通过检测重组突变分子的协同刺激造血活性有无改变来初步探讨CRD结构域在hSCGF分子中的生物学功能。研究结果表明,去掉完整CRD结构域的突变分子仍然具有造血刺激活性。据此推断CRD结构域在hSCGF分子中可能对于受体配体结合起辅助作用。     

一种减毒肺炎链球菌溶血素突变体的构建与表达

目的使用重叠PCR方法构建构建△Al46Ply突变体,原核可溶性表达△Al46Ply蛋白,并明确其毒力变化情况;分析肺炎链球菌溶血素（pneumolysin,Ply）在不同血清型肺炎链球菌（streptococcus pneumoniae,SPN）中的表达情况。方法以SPND39型基因组DNA为模板设计合成构建突变体pry基因所需引物;利用重叠PCR方法扩增合成△Al46ply突变体。通过溶血实验分析其溶血活性,利用中和试验验证△A146Ply诱导产生的特异性抗体中和野生Ply毒素溶血能力,并利用Western印迹检测5株不同血清型肺炎链球菌流行菌株中Ply蛋白表达情况。结果突变体基因测序结果显示,Plyl46位密码子GCT3个碱基被缺失,△Al46ply突变体构建成功,并实现了△Al46Ply的可溶性表达,得到纯度〉90％的重组蛋白。△A146Ply蛋白浓度为100000ng／ml亦未表现出溶血活性。△Al46Ply蛋白诱导产生的特异性抗体能够中和野生Ply毒素的溶血活性。Western印迹结果显示,△Al46Ply诱导产生的多克隆抗体可与国内临床常见4株肺炎链球菌有交叉反应。结论△Al46Ply蛋白是一种安全的肺炎链球菌疫苗候选分子,可刺激机体产生具有中和作用的特异性抗体。     

肌球蛋白轻链激酶CaM结合位点突变体的构建

目的:平滑肌肌球蛋白轻链激酶(myosin light chainkinase,MLCK)具有激酶活性和非激酶活性,在平滑肌收缩过程中起着关键酶调控的作用.为探寻MLCK的非激酶活性区域对MLCK活性的影响,本实验利用分子生物学技术构建了肌球蛋白轻链激酶CaM结合位点突变体,并纯化出重组的MLCK表达的蛋白质,为深入研究MLCK的非激酶活性在调节平滑肌收缩过程中的分子机制提供了实验基础.方法:利用野生型MLCK全长的cDNA序列设计CaM结合位点的突变引物,利用PCR技术进行定点突变,获得CaM结合位点的突变体(△CaM/MLCK).在大肠杆茵中表达重组CaM结合位点的突变体(△CaM/MLCK),通过亲和层析及凝胶过滤进行分离纯化重组蛋白,SDS-PAGE检测表达及纯化的重组蛋白.结果:构建重组MLCK钙调蛋白结合位点突变体(△CaM/MLCK),△CaM/MLCK在大肠杆菌中以可溶形式大量表达并得到纯化.结论:成功构建重组MLCK钙调蛋白结合位点突变体(△CaM/MLCK)并获得纯化的表达蛋白质.     

减毒李斯特菌载体运送HPV16 E7基因重组疫苗的构建及其生物学特性

单核细胞增生李斯特菌(Listeria monocytogenes,LM)是一种理想的肿瘤疫苗载体,本文旨在构建表达人乳头瘤状病毒(HPV)16型E7蛋白的减毒重组李斯特菌疫苗候选株并分析其生物学特性。利用同源重组技术将HPV16 E7基因定点整合至LMhly基因信号肽序列下游,获得减毒重组李斯特菌LM4△hly::E7,并对该重组菌进行生物学特性研究。实验结果表明,重组菌能够分泌表达具有免疫学活性的E7-LLO融合蛋白,大小约66 k Da;通过激光共聚焦扫描显微镜观察到重组菌能够在RAW264.7细胞胞内增殖。ELISA测定结果显示减毒重组菌能够诱导小鼠产生E7特异性抗体。重组菌在C57BL/6小鼠中LD50为3.863×10~9 CFU,低于亲本株4个数量级,通过组织切片观察到重组菌对小鼠肝脏及脾脏无明显病理变化。以上表明,本研究构建的分泌表达E7-LLO融合蛋白的减毒重组李斯特菌具有较好的安全性,为下一步研究其抗肿瘤作用提供了材料,并为研发宫颈癌的免疫治疗型候选疫苗奠定重要基础。     

TTF-1相关蛋白26磷酸化位点突变体的构建

目的制备TTF-1相关蛋白26（TAP26）的3个磷酸化位点（S48,S66和T219）的突变体（TAP26（S48→A48）、TAP26（S66→A66）和TAP26（T219→V219））。方法采用定点诱变PCR技术,分别突变掉TAP26的3个磷酸化位点（S48,S66和T219）,并获得TAP26的3个相应突变体。结果DNA序列分析结果显示TAP26的3个突变体序列正确。结论通过定点诱变PCR技术,成功构建了TAP26的3个突变体。     

茎瘤固氮根瘤菌ORS571 GGDEF和EAL结构域蛋白的预测及功能研究

[目的]环二鸟苷酸c-di-GMP是细菌中广泛存在的第二信使,能够调控多种细胞功能。c-di-GMP的合成与水解分别由含有GGDEF结构域和EAL结构域的蛋白催化。本研究针对茎瘤固氮根瘤菌ORS571的GGDEF和EAL结构域相关蛋白进行基因组学分析,并对三个同时含有GGDEF和EAL结构域的蛋白（AZC_3085、AZC_3226和AZC_4658）进行功能研究。[方法]利用SMART数据库对含有GGDEF和EAL结构域的蛋白进行结构域预测。利用CLUSTALW程序对蛋白序列进行比较分析。通过同源重组的方法构建突变株,并对突变株的细胞运动能力、胞外多糖合成、生物膜形成及与豆科宿主的结瘤等表型进行测定。[结果]茎瘤固氮根瘤菌ORS571中一共存在37个GGDEF和EAL结构域蛋白。突变株△4658的运动能力较野生型有下降,但是其胞外多糖合成能力、生物膜形成能力和竞争性结瘤能力较野生型有提高。此外,实验结果表明突变株△4658的胞内c-di-GMP水平高于野生型。突变株△3085和△3226的各种表型与野生型相比没有明显差异。[结论]茎瘤固氮根瘤菌ORS571编码如此大数量的GGDEF和EAL结构域蛋白,表明c-di-GMP可能在其信号转导过程中起到非常重要的作用。同时具有GGDEF和EAL结构域的蛋白AZC_4658对茎瘤固氮根瘤菌ORS571的运动能力、胞外多糖合成、生物膜形成及与宿主的结瘤起到一定的调节作用。     

Phosphorylation, ubiquitination and degradation of listeriolysin O in mammalian cells: role of the PEST-like sequence

Listeria monocytogenes is a bacterial pathogen that grows within the cytosol of infected host cells. Entry into the cytosol is largely mediated by a secreted bacterial cytolysin, listeriolysin O (LLO). In order to prevent host cell damage, the pore-forming activity of LLO is restricted to the phagosome. Compartmentalization of LLO requires a PEST-like sequence; PEST sequences can direct eukaryotic proteins for proteasomal degradation. Here we test the hypothesis that LLO's PEST-like sequence compartmentalizes pore-forming activity by targeting this bacterial protein for degradation in the host cytosol. We show that intracellular LLO was degraded in a proteasome-dependent manner, and that, prior to degradation, LLO was ubiquitinated and was phosphorylated within the PEST-like sequence. However, wild-type LLO and PEST region mutants had similarly short intracellular half-lives and both the wild-type and mutant proteins were stabilized by inhibitors of host proteasomes. Additionally, blocking host proteasomes did not cause toxicity in a wild-type infection, but enhanced the cytotoxicity of PEST region mutants. Together with the observation that PEST region mutants exhibit higher intracellular LLO levels than wild-type bacteria, these data suggest that LLO's PEST-like region does not mediate proteasomal degradation by the host, but controls LLO production in the cytosol.     

Identification of a PEST-like motif in listeriolysin O required for phagosomal escape and for virulence in Listeria monocytogenes

The hly-encoded listeriolysin O (LLO) is a major virulence factor secreted by the intracellular pathogen Listeria monocytogenes, which plays a crucial role in the escape of bacteria from the phagosomal compartment. Here, we identify a putative PEST sequence close to the N-terminus of LLO and focus on the role of this motif in the biological activities of LLO. Two LLO variants were constructed: a deletion mutant protein, lacking the 19 residues comprising this sequence (residues 32-50), and a recombinant protein of wild-type size, in which all the P, E, S or T residues within this motif have been substituted. The two mutant proteins were fully haemolytic and were secreted in culture supernatants of L. monocytogenes in quantities comparable with that of the wild-type protein. Strikingly, both mutants failed to restore virulence to a hly-negative strain in vivo. In vitro assays showed that L. monocytogenes expressing the LLO deletion mutant was strongly impaired in its ability to escape from the phagosomal vacuole and, subsequently, to divide in the cytosol of infected cells. This work reveals for the first time that the N-terminal portion of LLO plays an important role in the development of the infectious process of L. monocytogenes.     

The cholesterol-dependent cytolysin listeriolysin O aggregates rafts via oligomerization

The pore-forming toxin listeriolysin O (LLO) is the main virulence factor of Listeria monocytogenes. LLO is known to act as a pseudo cytokine/chemokine, which induces a broad spectrum of host responses that ultimately influences the outcome of listeriosis. In the present study we demonstrate that LLO is a potent aggregator of lipid rafts. LLO was found to aggregate the raft associated molecules GM1, the GPI-anchored proteins CD14 and CD16 as well as the tyrosine kinase Lyn. Abrogation of the cytolytic activity of LLO by cholesterol pretreatment was found not to interfere with LLO's ability to aggregate rafts or trigger tyrosine phosphorylation in cells. However, a monoclonal antibody that blocks the oligomerization of LLO was found to inhibit rafts' aggregation as well as the induction of tyrosine phosphorylation. This implies that rafts aggregation by LLO which is independent of cytolytic activity, is due to the oligomerization of its membrane bound toxin monomers. Thus, LLO most likely induces signalling through the coaggregation of rafts' associated receptors, kinases and adaptors.     

Lactobacillusacidophilus S-layer protein-mediated inhibition of Salmonella-induced apoptosis in Caco-2 cells

Surface layer (S-layer) proteins are crystalline arrays of proteinaceous subunits present as the outermost component of the cell wall in several Lactobacillus species. The underlying mechanism for how S-layer proteins inhibit pathogen infections remains unclear. To gain insights into the mechanism of the antimicrobial activity of Lactobacillus S-layer proteins, we examined how Lactobacillus S-layer proteins impact Salmonella Typhimurium-induced apoptosis in vitro in Caco-2 human colon epithelial cells. When Caco-2 cells infected with Salmonella Typhimurium SL1344, we found that apoptosis was mediated by activation of caspase-3, but not caspase-1. When Salmonella Typhimurium SL1344 and S-layer proteins were coincubated simultaneously, Caco-2 cell apoptosis was markedly decreased and the cell damage was modified, as evaluated by flow cytometry and microscopy. Detailed analyses showed that the S-layer proteins inhibited the caspase-3 activity and activated the extracellular signal-regulated kinases 1 and 2 (ERK1/2) signaling pathway. Taken together, these findings suggest that Lactobacillus S-layer proteins protected against Salmonella-induced apoptosis through reduced caspase-3 activation. In addition, Salmonella-induced apoptotic cell damage was modified by S-layer proteins through the ERK1/2 signaling pathway. This mechanism may represent a novel approach for antagonizing Salmonella infection.     

Bacillus subtilis inhibition of enterotoxic Escherichia coli-induced activation of MAPK signaling pathways in Caco-2 cells

The aim of this study was to test the hypothesis that Bacillus subtilis antagonises enterotoxic Escherichia coli (ETEC) infection through mitogen-activated protein kinases (MAPK) signaling pathways. In vitro studies were performed in which ETEC-infected Caco-2 cultured human intestinal cells were first incubated with B. subtilis and then ETEC adhesion and MAPK activation were determined. Incubation with B. subtilis was found to reduce ETEC adhesion in Caco-2 cells by 58–72 % in the adhesive experiments (competition, exclusion, and displacement assays). ETEC was able to induce extracellular signal-regulated kinases 1 and 2 (ERK1/2) and p38 MAPK activation, but not c-Jun amino-terminal kinase (JNK) activation, in Caco-2 cells. ETEC-induced phosphorylation of ERK1/2, but not of p38, was inhibited significantly in ETEC-infected Caco-2 cells treated with B. subtilis. These findings suggest that B. subtilis is able to inhibit ETEC infection through blocking ETEC-induced ERK1/2 activation in Caco-2 cells. The data could provide a rationale for the clinical application of B. subtilis in enteric pathogenic infection.     

EGFR-independent activation of ERK1/2 mediates growth inhibition by a PTPase antagonizing K-vitamin analog

The K-vitamin analog Cpd 5 or [2-(2-mercaptoethanol)-3-methyl-1,4-napthoquinone] is a potent cell growth inhibitor in vitro and in vivo, likely due to arylation of enzymes containing a catalytic cysteine. This results in inhibition of protein tyrosine phosphatase (PTPase) activity with resultant hyperphosphorylation of EGF receptors (EGFR) and ERK1/2 protein kinases, which are downstream to EGFR in the MAPK pathway. We used NR6 fibroblast cells, which lack endogenous EGFR and its variant cells transfected with different EGFR mutants to assess the contribution of the EGFR-mediated signaling pathway to Cpd 5-mediated ERK activation and cell growth inhibition. Cpd 5 treatment resulted in enhanced phosphorylation of EGFR at carboxyl-terminal tyrosines. This phosphorylation and activation of EGFR were found to be necessary neither for growth inhibition nor for the activation of the downstream kinases ERK1/2, since both occurred in EGFR-devoid mutant cells. U0126 and PD 098059, specific inhibitors of MEK1/2, the ERK1/2 kinases, antagonized both cell growth inhibition and ERK1/2 phosphorylation mediated by Cpd5. Cpd 5 was also found to inhibit ERK1/2 phosphatase(s) activity in lysates from all the cells tested, irrespective of their EGFR status. These results show that EGFR-independent ERK1/2 phosphorylation was involved in the mechanism of Cpd5 mediated growth inhibition. This is likely due to the observed antagonism of ERK phosphatase activity. A candidate PTPase was found to be Cdc25A, a recently identified ERK phosphatase.     

ERK1/2 mediates insulin stimulation of Na(+),K(+)-ATPase by phosphorylation of the alpha-subunit in human skeletal muscle cells

Insulin stimulates Na(+),K(+)-ATPase activity and induces translocation of Na(+),K(+)-ATPase molecules to the plasma membrane in skeletal muscle. We determined the molecular mechanism by which insulin regulates Na(+),K(+)-ATPase in differentiated primary human skeletal muscle cells (HSMCs). Insulin action on Na(+),K(+)-ATPase was dependent on ERK1/2 in HSMCs. Sequence analysis of Na(+),K(+)-ATPase alpha-subunits revealed several potential ERK phosphorylation sites. Insulin increased ouabain-sensitive (86)Rb(+) uptake and [(3)H]ouabain binding in intact cells. Insulin also increased phosphorylation and plasma membrane content of the Na(+),K(+)-ATPase alpha(1)- and alpha(2)-subunits. Insulin-stimulated Na(+),K(+)-ATPase activation, phosphorylation, and translocation of alpha-subunits to the plasma membrane were abolished by 20 microm PD98059, which is an inhibitor of MEK1/2, an upstream kinase of ERK1/2. Furthermore, inhibitors of phosphatidylinositol 3-kinase (100 nm wortmannin) and protein kinase C (10 microm GF109203X) had similar effects. Notably, insulin-stimulated ERK1/2 phosphorylation was abolished by wortmannin and GF109203X in HSMCs. Insulin also stimulated phosphorylation of alpha(1)- and alpha(2)-subunits on Thr-Pro amino acid motifs, which form specific ERK substrates. Furthermore, recombinant ERK1 and -2 kinases were able to phosphorylate alpha-subunit of purified human Na(+),K(+)-ATPase in vitro. In conclusion, insulin stimulates Na(+),K(+)-ATPase activity and translocation to plasma membrane in HSMCs via phosphorylation of the alpha-subunits by ERK1/2 mitogen-activated protein kinase.     

Requirement of the Listeria monocytogenes broad-range phospholipase PC-PLC during infection of human epithelial cells

In this study, we investigated the requirement of the Listeria monocytogenes broad-range phospholipase C (PC-PLC) during infection of human epithelial cells. L. monocytogenes is a facultative intracellular bacterial pathogen of humans and a variety of animal species. After entering a host cell, L. monocytogenes is initially surrounded by a membrane-bound vacuole. Bacteria promote their escape from this vacuole, grow within the host cell cytosol, and spread from cell to cell via actin-based motility. Most infection studies with L. monocytogenes have been performed with mouse cells or an in vivo mouse model of infection. In all mouse-derived cells tested, the pore-forming cytolysin listeriolysin O (LLO) is absolutely required for lysis of primary vacuoles formed during host cell entry. However, L. monocytogenes can escape from primary vacuoles in the absence of LLO during infection of human epithelial cell lines Henle 407, HEp-2, and HeLa. Previous studies have shown that the broad-range phospholipase C, PC-PLC, promotes lysis of Henle 407 cell primary vacuoles in the absence of LLO. Here, we have shown that PC-PLC is also required for lysis of HEp-2 and HeLa cell primary vacuoles in the absence of LLO expression. Furthermore, our results indicated that the amount of PC-PLC activity is critical for the efficiency of vacuolar lysis. In an LLO-negative derivative of L. monocytogenes strain 10403S, expression of PC-PLC has to increase before or upon entry into human epithelial cells, compared to expression in broth culture, to allow bacterial escape from primary vacuoles. Using a system for inducible PC-PLC expression in L. monocytogenes, we provide evidence that phospholipase activity can be increased by elevated expression of PC-PLC or Mpl, the enzyme required for proteolytic activation of PC-PLC. Lastly, by using the inducible PC-PLC expression system, we demonstrate that, in the absence of LLO, PC-PLC activity is not only required for lysis of primary vacuoles in human epithelial cells but is also necessary for efficient cell-to-cell spread. We speculate that the additional requirement for PC-PLC activity is for lysis of secondary double-membrane vacuoles formed during cell-to-cell spread.